Format

Send to

Choose Destination
Mol Ther. 2015 May;23(5):796-806. doi: 10.1038/mt.2015.54.

Genome editing technologies: defining a path to clinic.

Author information

1
National Institutes of Health, Bethesda, Maryland, USA. Electronic address: corrigaja@nhlbi.nih.gov.
2
National Institutes of Health, Bethesda, Maryland, USA.
3
University of California, Los Angeles, Los Angeles, California, USA.
4
Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
5
Georgia Institute of Technology, Atlanta, Georgia, USA.
6
University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USA.
7
University of Utah, School of Medicine, Salt Lake City, Utah, USA.
8
University Medical Center Freiberg, Freiberg, Germany.
9
Massachusetts General Hospital, Charlestown, Massachusetts; Harvard Medical School, Boston, Massachusetts, USA.
10
Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
11
Seattle Children's Research Institute and University of Washington, School of Medicine, Seattle, Washington, USA.
12
National Center for Tumor Diseases and German Cancer Research Center, Heidelberg, Germany.
13
Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA.
14
Stanford University, California, Stanford, California, USA.
PMID:
25943494
PMCID:
PMC4427885
DOI:
10.1038/mt.2015.54
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center